2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2016 Featured Talks » Anti-ErbB3 therapies – what do we know to date

Anti-ErbB3 therapies – what do we know to date

Birgit Schoeberl, PhD
Merrimack Pharmaceuticals

Birgit Schoeberl, PhD
Head of Research and Development
Merrimack Pharmaceuticals

Dr. Birgit Schoeberl is an internationally recognized leader in the application of Systems Biology to biology and drug development. At Merrimack, an oncology focused biotech company in Cambridge, MA, she leads early stage drug discovery and development. She joined Merrimack Pharmaceuticals in 2003 after doing postdoctoral training at MIT and was instrumental to building the company and its current pipeline. Dr. Schoeberl holds an M.S. in chemical engineering from the University of Karlsruhe, Germany, and a Ph.D. from the Max-Planck-Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.